Update shared on24 Oct 2025
Fair value Increased 2.46%Narrative Update on Bavarian Nordic
Analysts have raised their fair value price target for Bavarian Nordic from €244 to €250, citing modest improvements in valuation assumptions and financial projections.
What's in the News
- Officials in California have confirmed community spread of the new clade 1 Mpox strain among residents with no recent international travel. This marks the first instance of local transmission of this strain in the state (NBC).
- Bavarian Nordic reported topline results from a pediatric clinical study of its MVA-BN mpox/smallpox vaccine. The study showed that children aged 2-11 had a 2.5 times stronger immune response than adults, and the vaccine was well tolerated in both groups.
- The company plans to submit the pediatric vaccine data to the European Medicines Agency in 2026 for potential extension of its current approval to include children as young as 2 years old.
Valuation Changes
- Consensus Analyst Price Target has risen slightly from €244 to €250.
- Discount Rate has increased marginally from 4.92% to 4.97%.
- Revenue Growth projections remain essentially unchanged, at approximately negative 3.46%.
- Net Profit Margin forecast has stayed stable, at around 15.82%.
- Future P/E ratio has risen modestly from 23.31x to 23.92x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.